UK Medtech One Year Post-Brexit Vote: Still In The Land of Uncertainty
Executive Summary
The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting a while, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.
You may also be interested in...
'Hard' Brexit And Damage To MHRA's EU Medtech Reg Role Causing UK Concern
Few it seems want the UK MHRA to lose its strong input into EU medtech regulatory affairs. But the UK's brinkmanship on a hard Brexit and refusal to countenance any jurisdiction for the European Court of Justice post-Brexit could spell a severely diminished role for the UK health care regulator in EU matters after March 2019.
UK Medtechs Find Common Cause On Brexit In NHS Confed's Health Alliance
The UK has yet to get to the sharp end when it comes to the true effects of Brexit on future policy, trade and regulation, but the medtech industry and the national health-care provider, through the NHS Confederation, are pushing for a progressive and inclusive relationship with EU stakeholders. The Brexit Health Alliance is the latest embodiment of that drive.
German Electromed Industry View Of Brexit: We Can Cope
The German electromedical industry has surveyed it members on the potentially negative impacts of Brexit on business continuity. Findings suggest that the effects will be manageable.